Our Story
Orthogonal Peptides began with one simple question:
Why are some of the most promising medicines still so difficult — and expensive — to make?
In today's world, we are faced with monumental health challenges
3 Million
Patients lose their lives annually due Obesity-related Illnesses
5 Million
Patients lose their lives annually due to Microbial Infections
10 Million
Patients lose their lives annually due Cancer annually1
20 Million
People are currently diagnosed with Cancer annually
800 Million
People are currently diagnosed with Diabetes
$1 Trillion
Additional global Antimicrobial Resistance-related healthcare costs are projected by 2025
Our Vision
Enable a new era of drug discovery where no molecule is too complex to make.
Our Mission
Develop breakthrough technologies that simplify and improve the creation and purification of advanced peptide drugs — making complex medicines accessible and sustainable.
Core Values
Enabling Scientific Breakthroughs
We provide the tools and technologies that make the next generation of advanced therapeutics possible.
Accessibility and Affordability
We strive to make advanced therapies more accessible to patients worldwide by lowering the cost and complexity of drug development.
Excellence and Integrity
We hold ourselves to the highest standards of scientific rigor, transparency, and ethics.
Sustainability by Design
We are committed to reducing waste and environmental impact in every solution we develop.
Impact Through Collaboration
We work side by side with partners, scientists, and industry leaders to bring groundbreaking medicines to life.
Innovation Without Limits
We push the boundaries of science to unlock new possibilities in drug discovery.
Orthogonal Peptides was founded by a team of scientists from Imperial College London, we developed breakthrough technologies to overcome the limits of traditional peptide synthesis and purification. Our innovations now allow drug developers to create advanced peptide structures — including cyclic, scaffolded, and conjugate forms — with less waste, lower cost, and faster timelines.
Meet our Team
Professor Daryl Williams, Ph.D.
Interim Chief Executive Officer
30 Years of experience in international technology business as well as significant experience in university-industrial partnerships and collaborations
Max Elrad
Vice President Business Development
7 Years of experience with Life Sciences manufacturing business model, program management, and delivery as well as Pharmaceutical company partnerships
Dr. Othman Almusaimi, Ph.D.
Chief Technology Officer
10 Years of experience in peptide synthesis and primary inventor of our synthesis and drug discovery IP
Dr. Oscar Mercado-Valenzo, Ph.D.
Chief Scientific Officer
5 Years of experience in peptide purification and primary inventor of our peptide purification IP
Meet our Team
Professor Daryl Williams, Ph.D.
Interim Chief Executive Officer
30 Years of experience in international technology business as well as significant experience in university-industrial partnerships and collaborations
Dr. Othman Almusaimi, Ph.D.
Chief Technology Officer
10 Years of experience in peptide synthesis and primary inventor of our synthesis and drug discovery IP
Dr. Oscar Mercado-Valenzo, Ph.D.
Chief Scientific Officer
5 Years of experience in peptide purification and primary inventor of our peptide purification IP